Chronic myeloid leukemia after chemotherapy for adenocarcinoma of the rectum: A case report

Authors

  • Likhasit Sanglutong Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima
  • Somchai Insiripong Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima

Keywords:

Chronic myeloid leukemia, adenocarcinoma of rectum

Abstract

Chronic myeloid leukemia (CML) after chemotherapy for any primary malignancy has been occasionally reported. Herein we reported one definite case of CML who was diagnosed after the treatment of adenocarcinoma of the rectum. A 79-year-old Thai man was diagnosed with moderately differentiated adenocarcinoma of the rectum invading the urinary bladder. And he was treated with rectal resection and lymph nodes excision, followed by 5-fluoro-uracil and leucovorin therapy. He remained in complete remission for 1.5 years until he suddenly passed the hematochezia for one day and very high white blood cell and platelet counts without weight loss. The physical examination revealed no hepatosplenomegaly, no abdominal mass. The blood tests revealed: hemoglobin 10.6 g%, white blood cell 57,100/mm3, platelet 2,898,000/ mm3, neutrophil 68 %, lymphocyte 6 %, basophil 20 %, band 1 %. The chromosome study from the blood was positive for 46,XY,t(9;22) (q34;q11.2)[20] but negative for JAK-2 V617F mutation. Serum Carcinoembryonic antigen (CEA) level was continually normal both before the surgery and through out the follow-up. His definite diagnosis was established as CML, the accelerated phase with the history of 5-FU chemotherapy for the adenocarcinoma of the rectum. He did not accept further investigations for detecting the local recurrence of the rectal adenocarcinoma and refused tyrosine kinase inhibitor therapy. He could survive one year after the diagnosis of CML without serious symptom while this study was being reported. So far it could not be concluded that the occurrence of CML after the chemotherapy of the rectum adenocarcinoma isjust co-incidental or has any relationship.

Downloads

Download data is not yet available.

References

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring. Am J Hematol 2016;91:252-65. https://doi.org/10.1002/ajh.24275

Namakura H, Inokuchi K, Hanawa H, Yamaguchi H, Tamura H, Tajika K, et al. A case of Chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma. Ann Hematol 2000; 79:396-401. https://doi.org/10.1007/s002779900151

Alsop S, Sanger WG, Elenitoba-Johnson KS, Lim MS. Chronic myeloid leukemia as a secondary malignancy after ALK-positive anaplastic large cell lymphoma. Hum Pathol 2007;38: 1576-80.

https://doi.org/10.1016/j.humpath.2007.05.018

Zahra K, Ben Fredj W, Ben Youssef Y, Zaghouani H, Chebchoub I, Zaier M, et al. Chronic myeloid leukemia as a secondary malignancy after lymphoma in a child. A case report and review of the literature. Onkologie 2012; 35:690-3. https://doi.org/10.1159/000343952

Ocakç 1 S, Gör¬ml¬G, Sahin F, Özsan N, Zekio lu O, Uslu R, et al. Occurence of chronic myeloid leukemia in two breast cancer survivors after 4 years. Ege J Med 2011;50:141-4.

Walgraeve D, Verhoef G, Stul M, Cassiman JJ, Mecucci C, Van den BH, et al. Chronic myelogenous leukemia after treatment with I131 for thyroid carcinoma. Report of a case and review of the literature. Cancer Genet Cytogenet 1991;55:217-24. https://doi.org/10.1016/0165-4608(91)90080-E

Wang KL, Lin LY, Chen PM, Lin HD. Chronic myeloid leukemia after treatment with I131 for thyroid carcinoma. J Chin Med Assoc 2005;8:230-3. https://doi.org/10.1016/S1726-4901(09)70213-8

Gokel Y, Paydas S. Chronic myeloid leukemia in a patient with colon adenocarcinoma. Haematologia (Budap) 2002;32:501-3. https://doi.org/10.1163/15685590260461101

Kadikoylu G, Yavasoglu I, Barutca S, Meydan N, Bolaman Z. Chronic myeloid leukemia following the treatment of rectal adenocarcinoma. Med Oncol 2008;25:467-70. https://doi.org/10.1007/s12032-008-9061-3

Buxhofer-Ausch V, Hinterberger-Fischer M, Hinterberger W. Bcr-abl positive blast crisis of CML emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan. Eur J Haematol 2006;76:447-8. https://doi.org/10.1111/j.1600-0609.2006.00630.x

Vakili-Sadeghi M, Omranpour M. Chronic myeloid leukemia following colon cancer treatment: A case report and literature review. Caspian J Intern Med 2013;4:739-42.

Frustaci A, Breccia M, Cannella L, Stefanizzi C, Alimena G. Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature. Leuk Res 2009; 33:200 -1. https://doi.org/10.1016/j.leukres.2008.03.017

Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the WHO proposal. Cancer 2006;106:1306-15.

https://doi.org/10.1002/cncr.21756

Filiz AI, Sucullu I, Kurt Y, Karakas DO, Gulec B, Akin ML. Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients-Is it important? Clinics (Sao Paolo) 2009;64:287-94. https://doi.org/10.1590/S1807-59322009000400004

Peng C, Chen Y, Shan Y, Zhang H, Guo Z, Li D, et al. LSK derived lsk- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells. PLoS ONE 2012;7): e38614

https://doi.org/10.1371/journal.pone.0038614

Downloads

Published

2023-08-23

How to Cite

1.
Sanglutong L, Insiripong S. Chronic myeloid leukemia after chemotherapy for adenocarcinoma of the rectum: A case report. Chula Med J [Internet]. 2023 Aug. 23 [cited 2024 Dec. 24];61(3). Available from: https://he05.tci-thaijo.org/index.php/CMJ/article/view/456

Similar Articles

You may also start an advanced similarity search for this article.